Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Satellos Bioscience Inc (MSLE)

Satellos Bioscience Inc (MSLE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Satellos Reports 2025 Financial Results and Highlights Recent Company Progress GlobeNewswire - Fri Mar 27, 6:00AM CDT

Completed a US$57.2 million equity financing; commenced trading on the Nasdaq Global Market under the ticker “MSLE” on Feb. 6, 2026 Secured global regulatory clearances and initiated BASECAMP,...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos Presents Interim SAT-3247 Clinical and Biomarker Data in Duchenne Muscular Dystrophy at the 2026 MDA Clinical & Scientific Conference GlobeNewswire - Tue Mar 10, 6:00AM CDT

Interim observations from the Phase 2 TRAILHEAD study show continued improvement in handgrip strength, overall stability of elbow and shoulder strength in new dynamometry measurements Greater improvements...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos Announces Upcoming Oral and Poster Presentations at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference Business Wire - Tue Feb 24, 6:00AM CST

Satellos Bioscience Inc. (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases,...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos to Host Virtual KOL Event on SAT-3247 in Duchenne Muscular Dystrophy Business Wire - Wed Feb 18, 6:00AM CST

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos to Participate in Upcoming Investor Conferences Business Wire - Tue Feb 17, 6:00AM CST

Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit 2026 Business Wire - Tue Feb 10, 6:00AM CST

Satellos Bioscience Inc. (Nasdaq: MSLE , TSX: MSCL ) (“Satellos” or the “Company”), a clinical-stage biotechnology company focused on restoring natural muscle...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos Closes US$57.2 Million Public Offering in Canada and the United States, Including Exercise of Underwriters’ Option to Purchase Additional Shares Business Wire - Mon Feb 9, 4:00PM CST

Satellos Bioscience Inc . (Nasdaq: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle...

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)
Satellos Announces Pricing of US$50 Million Public Offering in Canada and the United States Business Wire - Fri Feb 6, 7:30AM CST

BASE SHELF PROSPECTUS IS ACCESSIBLE, AND PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS ON SEDAR+

MSLE : 5.87 (-2.81%)
MSCL.TO : 8.25 (-1.20%)

Barchart Exclusives

The Next Big AI Winner Might Not Be a Tech Company Barchart - Sat Apr 4, 10:30AM CDT
Lilly’s AI push shows how non-tech firms can dominate the next wave. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.